share_log

Benchmark Reiterates Buy on Biofrontera, Lowers Price Target to $7

Benzinga Real-time News ·  Jan 31, 2023 09:43

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and lowers the price target from $11 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment